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Abstract
Vaccination is one of the most successful approaches for controlling various viral diseas‐
es. Novel approaches will be needed to develop highly effective vaccines to prevent infec‐
tious diseases such as HIV. There are many aspects of HIV-1 biology that make the
development of an HIV vaccine difficult, including viral diversity, effective type of im‐
mune response, and suitable experimental model for preclinical trials. In spite of these
challenges, recent published results showed that a vaccine regimen could reduce HIV in‐
fection rates by 31% in Thailand. This vaccine named as RV144 is composed of a recombi‐
nant canarypox vector expressing three HIV-1 proteins as a prime and two different
recombinant HIV-1 gp120 envelope glycoproteins with alum adjuvant as a boost. In addi‐
tion, a subunit vaccine constructed from the viral envelope protein could be efficiently
developed using new techniques available through genetic engineering. The current
HIV-1 vaccine development focuses on antibody-based approaches. It was shown that
immunization with the viral envelope glycoprotein, gp120, should generate neutralizing
antibodies that would prevent infection, thereby yielding protective immunity. However,
HIV could develop many pathways to escape from antibodies that bind to the different
parts of the viral envelope molecules. Thus, the generation of neutralizing antibodies is
very difficult after viral infection or immunization protocols. Indeed, the viral envelope
molecules (Env) possess glycosylated residues that cover surface epitopes for binding
and neutralizing antibodies, even if the antibodies are produced. Furthermore, the tri‐
meric structures of envelope molecules show rapid conformational changes due to the in‐
teraction with viral cell surface receptors, CCR5/CXCR4 and CD4; thus the transition
state is very poor to be recognized by the immune system. Currently, studies focus on
generating stable trimeric envelope molecules (gp120/gp41) as immunogens that can in‐
duce neutralizing antibodies that can compete for binding to the cell surface receptors.
Altogether, it is clear that the design of a vaccine to elicit HIV-neutralizing antibodies is
not straightforward, and it causes major challenges in structural biology and immunolo‐
gy, several other studies strongly suggest cytotoxic T-lymphocyte (CTL)-based immune
responses against HIV infections. Indeed, CD8+ T cells play a major role in controlling vi‐
ral replication during primary HIV infections and in maintaining a stable viral load dur‐
ing the chronic phase. In this line, live-attenuated vaccines could elicit more potent and
durable pathogen-specific immune responses than inactivated or subunit vaccines. Gen‐
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erally, DNA vaccines are poorly immunogenic alone, and viral vector vaccines are inef‐
fective due to vector-specific immune responses if used repeatedly; hence, the two
approaches have often been tested in combination as prime-boost vaccination strategies.
Indeed, the prime-boost vaccination has been considered as an efficient strategy against
HIV infections. In this chapter, we will represent challenges to determine the best vaccine
strategies against HIV infections.
Keywords: HIV infection, Immune responses, Vaccination, DNA vaccine, Prime-boost
vaccine, Adjuvant, Challenges for HIV vaccine
1. Introduction
1.1. HIV infection and vaccination
According to recent reports, 35 million people were living with HIV-1 at the end of 2013, the
considerable majority being in Sub-Saharan Africa, with dynamic epidemics in Asia [1]. HIV
infection results in gradual loss of CD4+T lymphocytes, containing immune competence, and
progression to AIDS. Effective treatment with combined antiretroviral drugs decreases viral
load below detectable levels but cannot eliminate the virus from the body. Furthermore, the
success of combined antiretroviral drugs is hindered by accumulating drug toxicities and
chronic immune activation leading to increased risk of several non-AIDS disorders, even when
viral replication is inhibited. Therefore, there is a major need for therapeutic strategies as an
alternative to the combined antiretroviral drugs [2]. HIV vaccine strategies are expected to be
a critical component for controlling the HIV epidemic [3, 4]. Immunotherapy, or therapeutic
vaccination, aims to enhance existing immune responses against HIV or stimulate immune
responses. These immune responses should provide an efficient cure by controlling viral
replication and preventing disease progression in the absence of combined antiretroviral drugs
[2]. The cost-effective and different HIV-1 vaccine approaches have recently attracted a special
interest. Both antibodies and cell-mediated immune responses are considered to be important
to prevent HIV-1 infection in the mucosal compartment, i.e., the entry point for sexual
transmission [1]. A great majority of HIV-1 infections occur at mucosa during sexual contact.
Therefore, it is important to provide mucosal barrier protection against this entry by mucosal
vaccination. A number of mucosal routes of vaccination such as enteric oral or intranasal
vaccines have significant barriers that limit vaccine efficacy or cause safety risks. In contrast,
the sublingual region of the mouth could provide a simple route for mucosal vaccination with
immunogens, but this site does not always induce strong immune responses, especially when
protein antigens are used [5].
Currently, antibody-inducing vaccines are a major focus in the preventive HIV vaccine field
[6]. In addition, T-cell-based therapeutic vaccines have focused on three strategies: a) to
increase the levels of vaccine-induced responses, b) to enhance the responses targeting only
conserved regions of the virus, and c) to use replication-competent viral vectors [1]. Generally,
antiviral T-cell and B-cell responses play a crucial role in suppressing HIV replication during
chronic infection [7, 8]. Novel approaches of HIV treatment include both conventional
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therapeutic vaccines (i.e., active immunization strategies using HIV-derived immunogens) and
the use of checkpoint blockers such as anti-PD-1 antibodies. These complex therapeutic
strategies appear as promising approaches against HIV infection [7].
The biggest barrier for many vaccines is the pathogen’s variability. Thus, studies should be
further focused on the functionally most conserved regions of proteins common to many
variants, including escape mutants inducing both antibody and T-cell immune responses. For
vector-based vaccines, the “universal” subunit immunogens are efficiently delivered using
heterologous prime-boost regimens, which can be further improved using adjuvants and
delivery approaches [9–11]. Several studies have described the development of vaccine
strategies, including improved envelope proteins formulated with potent adjuvants, DNA and
vectors expressing mosaics or conserved sequences, capable of inducing strong relevant
immune responses, such as neutralizing antibodies (NAbs) and non-neutralizing antibodies,
CD4+ and CD8+ cell-mediated immune responses, mucosal immune responses, and immuno‐
logical memory. The type of immune response elicited by different immunogens can also
correlate with the risk of HIV infections. For example, IgG antibodies against the V2 loop of
gp120 are associated with a decreased risk of HIV infection, while Env-specific IgA antibody
is directly related to increased risk [12]. Generally, a combination of two independent ap‐
proaches, containing the induction of broadly neutralizing antibodies (bNAbs) to prevent or
reduce acquisition of infection and stimulation of effective CTL responses, is the currently used
technique to slow disease progression in advance infections [13].
Briefly, more than 20 years after the discovery of HIV, researchers are trying to design a
protective AIDS vaccine. The problem is the lack of basic knowledge about the immunological
requirements for the protection against HIV. Virus diversity and escape from immune
responses are the most important challenges to the development of an effective HIV vaccine.
In this chapter, we will represent the challenges to vaccine design against HIV biologically and
immunologically. Moreover, different vaccine strategies will be described to determine the
best strategies already focused on HIV infections. In this line, the relationship between HIV
biology and immunity will be demonstrated for the first time.
2. Immunogen-induced Neutralizing Antibodies (NAbs)
The most common tests for HIV infections rely on detecting antibodies against virus. Thus,
these tests can also detect antibodies induced by a candidate HIV vaccine. The detection of
vaccine-induced antibodies to HIV by serological tests is referred to as vaccine-induced
seroreactivity (VISR) [6]. Neutralizing antibodies are useful in identifying the neutralizing
epitopes of vaccine and for understanding the mechanism of potent and broad cross-neutral‐
ization, thereby providing a modality of preventive and therapeutic value [14, 15]. It has been
shown that some NAbs confer protection toward neonatal HIV-1 infection [16].
Various types of HIV-1 Env immunogens were developed that express epitopes for broadly
neutralizing antibodies and their precursors. There are three new structures proposed for the
HIV-1 Env trimer, which will be more immunogenic than previously used immunogens: a)
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minimal immunogens that are fragments of HIV-1 Env-neutralizing epitopes, b) intermediate
Env immunogens (e.g., monomeric Env gp120), and c) various forms of Env trimers [17]. To
date, these structures have not been capable of inducing the immune system to generate bNAbs
after vaccination. Thus, a successful vaccination for HIV-1 and induction of bNAbs will need
repetitive immunizations for a long time [17].
The current studies of HIV-positive patients with strongly neutralizing sera indicated that
the immune system is able to produce antibodies neutralizing up to 90% of HIV strains
[18].  The neutralizing antibodies bind to conserved gp120 sites,  and the identification of
these sites can help to design effective vaccines. Glycosylated residues (or carbohydrates)
have a key role because of binding broadly neutralizing antibodies to carbohydrates and
combining carbohydrate and peptide elements on gp120. However, carbohydrates partial‐
ly  cover  some  peptides  on  envelope  surface  recognized  by  bNAbs.  Thus,  the  use  of
engineered glycoproteins as vaccines for the stimulation of bNAbs is a subject of interest
in HIV vaccine design [18].Antibody responses to the HIV-1 envelope glycoproteins can be
classified into two: a) non-neutralizing responses directed to peptide epitopes expressed on
isolated  envelope  glycoproteins  but  not  on  the  native  envelope  trimers  responsible  for
mediating the entry of virus into target cells; b) broadly neutralizing antibody responses
targeting epitopes expressed on the native envelope trimers. Currently, many potent broadly
neutralizing  antibodies  have  been  isolated  to  stimulate  prophylactic  and  therapeutic
activities  in  animal  models.  These  antibodies  help  us  to  improve  vaccine  design  and
therapeutic  strategies  for  HIV-1  [19].  The  recent  characterization  of  new  epitopes  for
stimulating broadly neutralizing antibodies has encouraged studies in the synthesis of novel
antigenic constructs for the development of HIV-envelope-directed vaccines [20]. Thus, an
important step in vaccine design is the determination of antibodies and epitopes associat‐
ed  with  broad HIV neutralization.  Indeed,  immunogens  and/or  immunization  protocols
should be designed to increase antibody affinity maturation [1].
Regarding the studies, HIV-1 envelope gp120 is the target for neutralizing antibodies against
the virus. HIV-1 envelope gp120 exhibits a great degree of variability that causes a major
challenge for the development of vaccines against HIV/AIDS. Different approaches have been
used to improve immunogenicity of broadly neutralizing epitopes on HIV-1 gp120 with
limited success [21]. For example, immunogenicity of gp120 and its V3 epitopes was enhanced
when gp120 was co-injected with monoclonal antibodies (mAb) to the CD4-binding sites
(CD4bs). Indeed, the gp120/CD4bs complex was a potent immunogen for eliciting cross-
reactive functional NAbs against V3 epitopes [21]. In contrast, the membrane proximal external
region (MPER) of the gp41 subunit of the HIV-1 envelope glycoprotein (Env) includes epitopes
for recognizing bNAb as an important region in vaccine development. However, designing
an immunogen for the induction of bNAbs to MPER is difficult because of the relative
inaccessibility of the MPER in the native conformation of Env [22]. Therefore, a group of
oligomeric gp41 immunogens was designed to further expose MPER in a suitable conforma‐
tion. The immunogens comprised different gp41 N-heptad lengths and insertion of extra
epitopes and flexible C-termini. These immunogens were used in two different immunization
strategies, including gp41/gp140 proteins and gp41/gp160 DNA associated with various
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adjuvants and modalities. It was observed that the gp41 immunogens elicit higher levels of
MPER than the gp140 immunogens. In prime-boost strategies, the best MPER responses were
shown in the groups receiving gp41 DNA followed by gp41 protein. Several agents may
influence MPER immunogenicity such as the immunization route, dose, or adjuvant. Gener‐
ally, these data encourage the researchers for designing MPER immunogens with optimized
immunization protocols [22]. Furthermore, the aggregation of HIV-1 virions was detected by
antibodies (IgG) to the viral envelope glycoprotein (Env). Neutralizing antibodies directed to
a V3-base- and glycan-dependent epitope on gp120 and to the apex of the Env trimer, as well
as non-neutralizing antibodies to the epitope cluster I on the gp41-ectodomain, could aggre‐
gate virions, but the neutralizing antibody 2G12, which is specific for a glycan-dependent
monovalent epitope on gp120, could not aggregate. These data can potentially open the ways
for the development of HIV-1 vaccine [23].
3. Preventive HIV vaccines
The studies indicated that a successful vaccine candidate needs to elicit broad antibodies
targeting the Env protein. Immunogens targeting gp120 have been developed, which block
infection in monkeys. Attempts to induce antibody persistence were complicated by increasing
the number of HIV-target cells [24]. RV144 consisting of canary pox vector vaccine ALVAC-
HIV (vCP1521) prime and AIDSVAX®gp120 B/E boost was the first vaccine against HIV-1
infection achieved in clinical trial [1, 25]. The analysis of vaccine-induced immune responses
in vaccinated-infected and vaccinated-uninfected volunteers indicated that IgG specific for the
V1V2 region of gp120 was related to the decreased risk of HIV-1 infection, and plasma Env
IgA was directly associated with infection risk. Thus, RV144 studies indicated that Env is
essential and possibly sufficient to stimulate protective antibody responses against mucosally
acquired HIV-1. Efficacy trials were planned in heterosexual populations in southern Africa
and Thailand [1]. Generally, the studies of nonhuman primates suggest that Env is a necessary
component for a successful protection against viral infections. Two approaches are being
followed to induce Env-specific-antibody-mediated protection: a) vaccines that elicit potent
and broadly reactive neutralizing antibodies against viruses which are common in human
transmission, b) vaccines that induce antibody neutralizing only in less commonly transmitted
HIV strains, but that block HIV-1 infection by non-neutralizing (nNAbs) mechanisms [26, 27].
Monomeric gp120 HIV-1 envelope proteins alone failed to protect high-risk individuals
against infection. In fact, the level and breadth of elicited NAb were not sufficient for protection
[1]. Furthermore, the results indicated that IgG to linear epitopes in the V2 and V3 regions of
gp120 is part of a complex interaction of immune responses that contribute to the protection
in RV144 [28]. In RV144, Env IgG3 was correlated with decreased risk of HIV infection, a
response that declined rapidly compared to overall IgG responses. Indeed, the rates of Env-
specific IgG3 and V1/V2 IgG3 responses were high, and conversely IgG4 responses were
considerably low in recipients of the RV144 vaccine. These findings indicated that V2 IgG plays
a role in protection against HIV-1 infection. Generally, an increase in magnitude, affinity,
breadth, and importantly in frequency and durability of V2- and V3-specific antibodies of IgG3
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and IgG1 subclasses may confer a higher and more durable rate of protection against HIV-1
infection. The induction of cross-reactive V1V2-specific IgG raises the hypothesis of cross-clade
protection. Additional booster vaccinations may increase the antibody levels. Residual
antibody responses against gp120 were detected 6–8 years post vaccination in RV144 vaccinees.
Additional boosts increased plasma IgG gp120 and gp70 V1/V2 antibodies at titers higher than
those in RV144, while weak gp120 IgA responses were induced. These HIV-specific IgG
antibodies were also detected in rectal secretions while IgAs were undetectable [29–34].
Regarding the studies, HIV antibodies capable of preventing mucosal cell-free or cell-to-cell
HIV transmission are critical for the development of effective prophylactic and therapeutic
vaccines. The interactions between antigen-presenting cells (APCs) and HIV result in cell-to-
cell transmission of HIV. In the experimental macaque model, data indicated that the broadly
neutralizing antibodies are capable of neutralizing an extensive range of HIV strains, prevent‐
ing cell-to-cell transfer, and protecting from infection[35]. In addition, IgG Fcg receptor (FcgR)-
mediated inhibition of antibodies at the mucosal site may play a role in protection against HIV
mucosal transmission. On the contrary, mucosal IgA antibodies may be effective in protection
against HIV sexual transmission. Thus, the determination of inhibitory effects of antibodies is
critical for evaluating protection in HIV vaccines [35]. Furthermore, the majority of the
antibodies against different viral proteins described a marker (shared idiotope) that is
recognized by the monoclonal antibody 1F7. This shared idiotype on antibodies induced by
HIV-1 was involved in the immune memory mechanism linking the early and late antibodies,
the so-called back-boost effect. This finding was supported by auto-antibodies that bind to the
1F7 idiotope in sera of HIV-1-infected individuals. The expression of a shared idiotope in
antibodies could provide a strategy to stimulate B cells selected to produce antibodies against
HIV-1 and HCV, suggesting their implications in vaccine design [36].
The use of potent adjuvants may also enhance antigen-specific antibody responses. Several
adjuvants have been tested in nonhuman primates and humans indicating a significant benefit
of HIV envelope proteins formulated with MF59 and AS01 adjuvants. A study indicated that
alum protected macaques from simian immunodeficiency virus (SIV)mac251 infection, while
MF59 did not protect despite its ability to elicit higher systemic T-cell and antibody responses.
Adjuvant-associated differences in the homing of plasmablasts and induction of key cellular
signaling pathways may explain these effects. The formulation of HIV-1 gp120 with MPLA
and alum induced significantly higher levels of neutralizing antibodies and T-cell lympho‐
proliferation compared to alum, MF59, or MPLA alone. Importantly, antibodies to gp70 V1V2
(subtypes B, C, and CRF01 AE) were induced more rapidly, to a higher magnitude and with
a greater durability than alum-adjuvanted gp120 [37–42]. Also, the formulation of antigens
with solid nanoparticles may prolong the duration of antibody responses by increasing antigen
retention locally in the tissues driving B-cell responses, enhancing dendritic cell (DC) antigen
presentation, and the development of CD4+ Th cells that provide cytokines and signals that
are required to initiate somatic hypermutation and affinity maturation for effective B-cell
memory [1]. Furthermore, the ability of two mucosal adjuvants, including α-galactosylcera‐
mide (α-GalCer) as a potent stimulator of natural killer (NK) T cells and CpG-oligodeoxynu‐
cleotide (CpG-ODN) as a TLR9 agonist, was evaluated to enhance immune responses against
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clade C gp140 HIV-1 envelope protein antigen. The results showed that CD4+ and CD8+ T-cell
responses in systemic and mucosal tissues were significantly higher in mice immunized with
gp140 in the presence of either α-GalCer or CpG-ODN and further enhanced when both
adjuvants were used. Also, the use of two adjuvants and especially their combination effec‐
tively increased gp140-specific serum IgG and vaginal IgA antibody levels. Memory T-cell
responses detected at 60 days after immunization revealed that α-GalCer is more potent than
CpG-ODN, and the combination of α-GalCer and CpG-ODN adjuvants was more effective
than either alone [5]. Another approach is called B-cell lineage vaccine design. In this line, the
recombinant antibodies belonging to bNAb members were used to determine HIV-1 envelope
constructs as immunogens in a prime-boost strategy. These envelope constructs utilize the
naïve B-cell repertoire residing in bone marrow and secondary lymphoid tissues in vivo and
subsequently stimulate B-cell evolution until bNAb-producing cells are elicited [43, 44].
The nNAb B-cell progenitors become activated and internalize Env compared with bNAb B-
cell progenitors. The reports showed that rational immunogen modifications can reduce the
activation of naïve B cells that lead to such nNAbs, while promoting the activation of naïve B
cells that result in germline-reverted bNAbs [43, 44]. A number of potent broadly neutralizing
antibodies have been identified from HIV-infected individuals although the generation of
bNAbs using traditional vaccine approaches has been obscure. The researchers tested a single
dose of 3BNC117 or 10-1074 (mAb specific for the CD4-binding site and the V3 region,
respectively) and also a combination of both antibodies. The data showed a total decline in
viral loads post infusion in simian-human immunodeficiency virus (SHIV)-infected macaques.
Another approach to the generation of bNAbs is to circumvent “normal” immune responses
and direct non-lymphoid cells to produce bNAbs in vivo using gene therapy. Vectored
immunoprophylaxis (VIP) is a gene therapy method in which transgenes encoding bNAbs are
delivered directly into muscle tissue where bNAbs are produced. Two recent animal studies
demonstrated that VIP could generate modest titers of NAb that can effectively prevent in
vivo HIV infection in a humanized bone marrow–thymus–liver (BLT) HIV infection model and
a simian immunodeficiency macaque infection model [7]. Recent findings showed that adeno-
associated virus (AAV)-delivered broadly neutralizing antibodies can inhibit HIV replication.
Indeed, a single injection of AAV could generate long-term antibody responses as a therapeutic
approach in the lack of antiretroviral drugs. Induction of vector-mediated antibodies could
inhibit cell-to-cell transmission and replication of HIV. This result represented an alternative
to immunogen-based vaccine design and a novel therapeutic intervention by enabling
particular manipulation of humoral immunity [45, 46].
A challenge for HIV-1 immunogen design is the induction of neutralizing antibodies against
neutralization-resistant (Tier-2) viruses that control human transmissions. A soluble recombi‐
nant HIV-1 envelope glycoprotein trimer possessing a native conformation (BG505 SOSIP.664)
could induce NAbs potently against the sequence-matched Tier-2 virus in rabbits but weaker
and similar responses in macaques. The trimer also stably stimulated cross-reactive NAbs
against more sensitive (Tier-1) viruses. Tier-2 NAbs recognized conformational epitopes that
differed between animals and in some cases overlapped with those recognized by broadly
neutralizing antibodies, whereas Tier-1 responses targeted linear V3 epitopes. A second trimer,
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B41 SOSIP.664, also induced a strong autologous Tier-2 NAb response in rabbits. Thus, native-
like trimers may represent a promising starting point for developing HIV-1 vaccines directed
at inducing bNAbs [47].
The goal of an HIV vaccine is to generate robust and durable protective antibody. Thus, it is
important to induce CD4+ T-follicular helper (TFH) cells. However, very little is known about
the TFH response to HIV vaccination and its relative contribution to magnitude and the quality
of vaccine-elicited antibody titers [48]. In this line, a DNA/modified vaccinia virus Ankara SIV
vaccine with and without gp140 boost in aluminum hydroxide was administered in rhesus
macaques. The studies indicated that booster immunization with modified vaccinia virus
Ankara induces a distinct and transient accumulation of proliferating CXCR5+ and CXCR5−
CD4 T cells in blood at day 7 post-immunization, and the frequency of the former but not the
latter correlated with TFH and B-cell responses in germinal centers of the lymph node.
Furthermore, gp140 boost elicited a skewing toward CXCR3 expression on germinal center
TFH cells, which was strongly associated with longevity, avidity, and neutralization potential
of vaccine-elicited antibody response. However, CXCR3+ cells preferentially expressed the HIV
co-receptor CCR5, and vaccine-induced CXCR3+CXCR5+ cells showed a moderate positive
association with peak viremia following SIV251 infection. These data demonstrated that
vaccine regimens eliciting CXCR3-biased TFH cell responses favor antibody persistence and
avidity but may prompt higher acute viremia in advance infections [48, 49].
Generally, broadly neutralizing antibodies specific for conserved epitopes on the HIV-1
envelope (Env) are believed to be essential for the protection against multiple HIV-1 clades.
Recently, an HIV vaccine incorporating the molecular adjuvants B-cell activating factor (BAFF)
and a proliferation-inducing ligand (APRIL) was designed with the potential to facilitate the
maturation of polyreactive and autoreactive B cells as well as to enhance the affinity and/or
avidity of Env-specific antibodies. The results indicated that mice immunization with a DNA
vaccine encoding BAFF or APRIL multitrimers, together with IL-12 and membrane-bound
HIV-1 Env gp140, induced neutralizing antibodies against Tier-1 and Tier-2 viruses. The
APRIL-containing vaccine was especially effective at generating Tier-2 neutralizing antibodies
following a protein boost. Notably, BAFF and APRIL did not cause B-cell expansion or an
increase in total IgG. Thus, BAFF and APRIL multitrimers were proposed as promising
molecular adjuvants for inducing bNAbs against HIV-1 infection [50].
4. Stimulation of cell-mediated immune responses
A successful HIV vaccine must either completely prevent infection or eliminate the first
round of infected CD4 T cells before the latent pool of HIV-infected cells is  established.
Thus, an effective HIV vaccine requires high levels of protective immunity at the time of
virus contact with the host, and it cannot rely on memory immune responses to occur. CD8
T cells can effectively kill HIV-infected T cells, but in most cases of acute HIV infection,
the virus rapidly escapes. For example, anti-HIV CD8 CTL activity is capable of eliminat‐
ing virus-infected T cells in the setting of vaccination with an attenuated rhesus cytomega‐
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lovirus  (rhCMV) containing simian immunodeficiency virus  genes,  but  in  the  setting of
acute HIV infection, the transmitted/founder virus usually escapes from CD8 T-cell control
[51]. CTL responses targeting specific HIV proteins (e.g.,  Gag) have been associated with
relative control of viral replication in vivo.  In a SIVmac251 intravenous challenge model,
breadth of Gag CTL epitope recognition correlated with control of viremia peak [1]. These
data have demonstrated that CD8+ T cells are associated with the control and eradication
of early retrovirus infections [17].
The  vaccine  trials  were  focused  on  whether  cell-mediated  immune-response-inducing
vaccines can prevent infection or reduce post-infection plasma viral load [1]. Vaccinees with
HLA alleles associated with HIV-1 control had a significantly lower mean viral load over
time. Interestingly, the most highly conserved epitopes were detected at a lower frequen‐
cy,  suggesting  that  stronger  responses  to  conserved  sequences  may  be  as  important  as
breadth  for  protection  [52,  53].  Interestingly,  heterologous  vector  prime-boost  regimens
enhanced  immunity  by  increasing  the  magnitude,  onset,  and  multi-functionality  of  the
insert-specific  cell-mediated immune responses  compared to  homologous  regimens  [54].
New progress has been made in overcoming HIV-1 diversity through induction of cross-
reactive  T-cell  responses  to  HIV-1  by  vaccines  designed  in  silico  (called  conserved  and
mosaic  vaccines)  [17].  Polyvalent  mosaic  immunogens  derived  by  the  recombination  of
natural HIV-1 strains were designed to induce cellular immune responses that recognize
genetically diverse circulating virus isolates. Increasing the breadth and depth of epitope
recognition may contribute to the protection against infection by genetically diverse viruses
and also to the control of variant viruses that emerge as they mutate away from recogni‐
tion by CTLs. For example, mosaic HIV-1 Gag, Pol, and Env antigens expressed by Ad26
vectors  markedly  augmented  both  the  breadth  and  depth  without  compromising  the
magnitude  of  antigen-specific  T-lymphocyte  responses  as  compared  with  consensus  or
natural  sequence HIV-1 antigens in rhesus monkeys [55,  56].  An alternative to  multiva‐
lent wild-type or mosaic vaccines is the use of conserved element immunogens as a novel
and effective strategy to broaden responses against highly diverse pathogens by avoiding
decoy epitopes,  while focusing responses to critical  viral  elements for which few escape
pathways exist. Priming with conserved elements boosted with the complete immunogen
induced broad cellular  and humoral  immunity focused on the conserved regions of  the
virus. In contrast, full-length HIV-1 immunogens elicited greater magnitude and compara‐
ble  breadth  of  T-lymphocyte  responses  to  conserved  HIV-1  regions  compared  with
conserved-region only HIV-1 immunogens in rhesus monkeys [57, 58].
An important point is the use of replicating vector. A replication-competent rhesus cytome‐
galovirus vaccine expressing SIV proteins induced and maintained high frequency of SIV-
specific CD4+ and CD8+ T-cell effector memory responses at extra-lymphoid sites without
measurable antibody responses to SIV. Half of vaccinated monkeys showed a severe control
of three routes of SIVmac239 transmission including intrarectal, intravaginal, and intravenous.
The conservation of particular cytotoxic epitopes does make them good candidates for a global
HIV-1 vaccine [59, 60].
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5. Therapeutic HIV vaccines
Recent studies have focused on the improvement of effective prophylactic and therapeu‐
tic  approaches to  combat  persistent  viral  infections.  Therapeutic  vaccines  for  HIV infec‐
tion should aim to elicit antiviral CD8 T cells (CTLs), CD4 T cells, and neutralizing antibody
since these immune responses control viral replication [7, 61]. It is critical to generate broad
cellular responses as HIV mutates very rapidly to escape immune system. In addition, recent
studies  determined  that  T-follicular  helper  cells  constitute  a  significant  source  of  virus
production  and  contribute  to  the  total  viral  reservoir.  Since  these  cells  reside  in  B-cell
follicles/germinal centers,  it  may be critical  to generate CD8 T cells that can home to B-
cell follicles and exert immune response on these cells. The HIV-specific CD4 T-cell response
is also important for maintaining the functional CD8 T-cell and B-cell responses. Howev‐
er,  these HIV-specific CD4 T cells could also serve as potential  targets for virus replica‐
tion [7]. Interestingly, CD4 T cells with cytolytic function have been shown to be associated
with enhanced viral control, although it is demonstrated whether these responses can be
primed by vaccination. The function of dendritic cells may be also critical for generating a
protective cellular and humoral immune response, as chronic HIV infections are associat‐
ed with impaired DC function. Thus, therapeutic vaccines may also need to use strategies
such as adjuvants to enhance the function of innate immunity [7].
Several therapeutic vaccine strategies have already been used such as live-attenuated mi‐
crobes, viral vectors, and dendritic cell-based vaccines that led to suppress and/or clear
infections. Among them, improved DNA vaccines have emerged as a promising candidate for
the treatment of infectious diseases especially HIV infections [61–63]. Some strategies have
been considered to improve immune responses stimulated by DNA vaccines such as in vivo
efficient DNA delivery systems, co-delivery with molecular adjuvants as well as the develop‐
ment of potent heterologous prime-boost regimens [61, 62, 64]. DNA vaccines have been
utilized as candidate HIV vaccines because of their ability to generate cellular and humoral
immune responses, the lack of anti-vector response allowing for repeat administration, and
their ability to prime the response to viral-vectored vaccines. Because the HIV epidemic has
unreasonably affected the developing world, the favorable thermostability profile and relative
ease and low cost of manufacture of DNA vaccines offer additional advantages. In vivo
electroporation (EP) has been utilized to improve immune responses to DNA vaccines as
candidate HIV-1 vaccines alone or prime-boost regimens with both proteins and viral-vectored
vaccines in several animal models, and recently, in human clinical trials [65]. In addition,
intradermal electroporation of HIV DNA was well tolerated. Strong cell- and antibody-
mediated immune responses were elicited by the HIV-DNA prime and HIV-Modified Vaccinia
Ankara (MVA) boosting regimen, with or without intradermal electroporation use [66]. DNA
vaccines have an intrinsic bias toward generating cellular immunity against intracellular
pathogens. By manipulating the DNA formulation and delivery, effective antibody responses
can also be induced. For instance, studies showed that the immunized monkeys with DNA
vaccine developed HIV-specific T-cell immune responses that persisted for months [62].
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The use of live-attenuated invasive bacteria as a carrier for DNA-based vaccines has previously
been reported [67]. Immunization with recombinant invasive bacteria including Shigella,
Salmonella, and Listeria carrying plasmid DNA (pDNA) vaccines has been shown to induce
protective immune responses in mice. The use of human enteric bacteria is especially useful
due to their ability to infect human colonic mucosa, and their tropism for the activation of
dendritic cells and macrophage of internal mucosa. Thus, they are very efficient for the delivery
of DNA vaccines to APCs in the mucosa resulting in stimulation of potent systemic and local
immune responses. Such responses may be critical for the development of an effective
prophylactic HIV vaccine, because a large number of HIV transfer through human mucosal
routes [67]. For instance, a live-attenuated strain of Salmonella typhimurium was used to deliver
plasmid orally and showed an adjuvant role through the release of various cytokines [68]. In
addition, intranasal immunization of mice with live recombinant Shigella cells induced an HIV
Gag-specific cellular immune response similar to that observed by intramuscular injection of
naked DNA. Importantly, a strong boosting effect was obtained in mice primed with DNA,
suggesting the efficacy of bacterial vectors in prime-boost vaccination regimens [67]. The
studies indicated that a novel vaccine delivery system using bacterial ghosts (BGs) can be
considered as an efficient and nontoxic delivery system for DNA vaccines in vitro and in vivo.
In this line, a new strategy of HIV vaccine delivery was designed using Salmonella typhi Ty21a
bacterial ghosts. The data showed that Ty21a BGs loaded with an HIV gp140 DNA vaccine
(Ty21a BG-DNA) are easily taken up by murine macrophage cells (RAW264.7), and gp140 is
efficiently expressed in these cells. Peripheral and intestinal mucosal anti-gp120 antibody
responses in mice vaccinated with BGs–DNA vaccine were significantly higher than those in
mice immunized with naked DNA vaccine. The enhancement of antibody responses was
associated with BG-induced production of IL-10 through TLR4 pathway [69].
Attenuated virus vaccines have traditionally been potent and relatively easy to produce and
deliver. Vaccination with a live virus results in high intracellular synthesis of viral proteins.
This high-level expression stimulates strong cellular and humoral immune responses and
results in the production of long-lasting memory B and T cells. However, attenuated HIV
vaccines replicate strongly in animal models to retain residual virulence. Recent studies
indicated that priming with a DNA vaccine induces a Th1 response that can be boosted by the
subsequent administration of a viral vector encoding the same gene. This prime-boost strategy
elicited strong protective immunity in several primate models [70]. Currently, immunogenicity
of a highly attenuated vaccinia virus with low neuro-virulence, LC16m8 strain, was studied as
an HIV vaccine vector. The data showed that the recombinant vaccinia virus-based vaccine
(vLC-Env) combined with DNA vaccine expressing the HIV env gene (pCAG-Env) produces
a protective immune response against HIV infection in BALB/c mice. Vaccination of vLC-Env
alone induced much higher HIV-specific humoral and cellular immune responses than that of
pCAG-Env. Priming with pCAG-Env further enhanced vLC-Env-induced immune responses,
especially cell-mediated immune response. In addition, administration of vLC-Env-infected
dendritic cells to mice generated a high cellular immune response. These results demonstrated
that priming with pCAG-Env and boosting with vLC-Env represents a potential candidate for
vaccination against HIV infection [70]. A few studies have used DC presenting either the
autologous virus or virus-derived peptides as therapeutic vaccines (DC-based vaccines) in
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macaques and humans. They also showed that a similar approach could successfully control
HIV replication in humans. Similarly, a recent study showed that an efficient HIV-1-specific
immune response could be generated using an autologous monocyte-derived DC (MDDC)
transfer. Thus, HIV-specific immune responses could be elicited by DC-based therapeutic
vaccinations. In general, therapeutic vaccinations should be explored as a combination therapy
with other immune modulators to achieve a functional cure (i.e., long-term control of virus
replication in the absence of antiretroviral therapy) [7].
There is growing interest in the role of anti-HIV antibody-dependent cellular cytotoxicity
(ADCC) antibodies in the prevention and control of HIV infection. Passive transfer studies in
macaques supported a role for the Fc region of antibodies in the prevention of simian–human
immunodeficiency virus infection. The Thai RV144 HIV-1 vaccine trial induced anti-HIV
ADCC antibodies that may play a role in the partial protection observed. Several studies
showed a role for ADCC antibodies in slowing HIV disease progression. However, HIV
evolves to escape ADCC antibodies, and chronic HIV infections cause the dysfunction of
effector cells such as natural killer cells that mediate the ADCC functions. Furthermore, four
recent studies showed that the HIV-1 Vpu protein, by promoting release of virions, reduces
the capacity of ADCC antibodies to recognize HIV-infected cells [71]. On the contrary, The
HIV-1 transactivator of transcription (Tat) is a key HIV virulence factor, which plays critical
roles in virus gene expression, replication, transmission, and disease progression. The results
indicated that Tat-induced immune responses are necessary to restore immune homeostasis,
to block the replenishment and to reduce the size of the viral reservoir. Anti-Tat antibodies are
uncommon in natural infection and, when present, correlate with the asymptomatic state and
lead to lower or no disease progression. Hence, targeting Tat represents a pathogenesis-driven
intervention [72].
6. Adjuvants
Although the importance of DNA vaccines, especially as a priming immunization, has been
well proved in different HIV vaccine studies, the immunogenicity of DNA vaccines is generally
moderate. Novel adjuvant is necessary for improving the immunogenicity of DNA vaccine
[73]. Multiple groups have demonstrated the potential of co-administering plasmid DNA that
express cytokines, chemokines, or co-stimulatory molecules together with plasmids encoding
target viral antigens [74]. The potency of DNA vaccines can be developed by the co-delivery
of plasmid-encoded molecular adjuvants. The pDNAs encoding granulocyte-macrophage
colony-stimulating factor (GM-CSF), hematopoietic factor fms-like tyrosine kinase 3 ligand
(Flt-3L), and interleukin-12 (IL-12) could markedly enhance cell-mediated immune responses
elicited by an HIV-1 env pDNA vaccine in BALB/c mice [74]. Plasmid GM-CSF also increased
the immune responses elicited by DNA vaccines expressing HIV-1 Gag and Nef-Tat-Vif. In
addition, the use of pGM-CSF as a vaccine adjuvant appeared to increase antigen-specific
proliferative responses and the percentage of polyfunctional memory CD8+ T cells. Co-delivery
of pFlt-3L with pGM-CSF did not result in a further increase in adjuvant activity. However,
the co-administration of pGM-CSF with pIL-12 significantly enhanced Env-specific prolifera‐
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tive responses and vaccine efficacy in the murine vaccinia virus challenge model relative to
mice immunized with the env pDNA vaccine adjuvanted with either pGM-CSF or pIL-12 alone
[74]. In another study, co-administration of the HIV-1 DNA vaccine with pIL-12 and pGM-
CSF by topical application to the skin enhanced the levels of both the HIV-specific cytotoxic
T-lymphocyte response and delayed-type hypersensitivity (DTH). Indeed, the skin is accessi‐
ble for generating immune responses by both intradermal injection and topical use of gene
delivery vectors [75]. In addition, co-administration of plasmids encoding the codon-opti‐
mized GM-CSF sequence with the HIV-1 Gag DNA vaccine resulted in a strong antibody and
CTL response and a protective immune response against infection with recombinant vaccinia
virus expressing HIV-1 Gag [76]. On the contrary, researchers strongly support the use of IL-6
or IL-15 as a cytokine adjuvant in HIV DNA vaccination. The data indicated that intranasal
administration of DNA vaccine and pIL-15 can enhance Th1-dependent HIV-1-specific cell-
mediated immunity. However, co-injection of pIL-15 with pIL-2 or pIL-12 did not show any
synergistic effect on the immune responses induced by DNA vaccine in vivo [77]. Furthermore,
the immunogenicity of HIV-1 DNA vaccine expressing the chimeric gene Gag-gp120 (pVAX1-
Gag-gp120) was increased by co-inoculating pVAX1-IL6 in BALB/c mice [78]. The studies
demonstrated that in-frame fusion of tumor necrosis factor alpha (TNF-α), DNA to DNA,
encoding a large fragment of HIV gp120 could enhance Th1 immune responses against gp120
antigen. Also, in-frame fusion of IFNγ-encoding DNA at the 5′ end of the chimeric molecule,
to create a tripartite fusion, had no additional effect on immunogenicity [79]. A number of
studies have shown that α-galactosylceramide, a natural killer T-cell (NKT) ligand, was
applied as an adjuvant for various vaccines, including viral, parasite, and protein-based
vaccines. The α-GalCer was able to enhance HIV-specific antibody responses. Furthermore,
co-administration of α-GalCer with suboptimal doses of DNA vaccines greatly increased
antigen-specific CD4+ and CD8+ T-cell responses. The level of cell-mediated immune responses
in mice vaccinated with 5 μg of DNA in the presence of α-GalCer was similar to that of mice
vaccinated with 50 μg of DNA in the absence of α-GalCer [80].
Recombinant adjuvants composed of a fusion between surfactant protein-D (SP-D) and either
CD40 ligand (CD40L) or GITR ligand (GITRL) were previously shown to enhance HIV-1 Gag
DNA vaccines. It was demonstrated that similar fusion constructs composed of the TNF
superfamily ligands (TNFSFL) including 4-1BBL, OX40L, RANKL, LIGHT, CD70, and BAFF
can also enhance immune responses to an HIV-1 Gag DNA vaccine. Importantly, the SP-
D-4-1BBL, SP-D-OX40L, and SP-D-LIGHT constructs enhanced CD8+ T-cell avidity and CD8+/
CD4+ T-cell proliferation 7 weeks after vaccination [81]. Also, the SP-D-OX40L, SP-D-LIGHT,
and SP-D-BAFF constructs increased Gag-specific IL-2 secretion in memory T cells, suggesting
their potency to elevate the number of self-renewing Gag-specific CD8+ and CD4+ T cells.
Finally, the SP-D-OX40L and SP-D-CD70 adjuvants augmented IgG2a but not IgG1 antibody
responses in the immunized animals. Interestingly, the B-cell-activating protein BAFF did not
enhance anti-Gag antibody responses when administered as an SP-D fusion adjuvant, but
augmented CD4+ and CD8+ T-cell responses. Indeed, various SP-D-TNFSFL fusion constructs
can enhance immune responses following DNA vaccination with HIV-1 Gag expression
plasmid [81]. Several studies indicated that 4-1BB and 4-1BB ligand (4-1BBL) interactions are
important for inducing robust CTL responses and also long-lived memory T cells. Recently,
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plasmid DNAs expressing either the membrane bound or soluble form of 4-1BBL were
designed to enhance the Gag DNA vaccine as an adjuvant. The data showed that 4-1BBL DNA
increased the Gag-specific IgG and cellular immune responses. Importantly, the expression of
Gag and 4-1BBL from the same plasmid was critical for the adjuvant activity [82].
To improve the immunogenicity of DNA vaccines, some studies were focused on the immu‐
noglobulin (Ig) fusion antigen. These reports showed that cytokine-coding plasmids fused
with Ig have higher expression efficiency and better adjuvanticity. Furthermore, these
plasmids have features that make them useful such as augmentation of half-life in vivo,
formation of a multivalent antigen, and solubilization of hydrophobic proteins [83]. The
possibility of increasing HIV gp120-specific cellular immune responses was determined in
mice using a DNA vaccine encoding a mouse Ig fragment fused with gp120 in two directions
(gp120-Ig or Ig-gp120). In vitro expression analysis revealed that the efficiency of HIV gp120
protein expression was higher in cells transfected with the gp120-Ig-coding plasmid
(pGp120Ig) than in those transfected with the gp120 and Ig-gp120 expression plasmids
(pGp120 and pIgGp120, respectively). The gp120-Ig-coding plasmid elicited more HIV-specific
CD8+ T cells and effector memory CD8+ T cells than pGp120 in immunized mice. Furthermore,
pGp120Ig significantly reduced the viral load after challenge with an HIV Env gp160-
expressing vaccinia virus. These results represented that covalent antigen modification with
an Ig sequence can modulate antigen-specific cellular immune responses [83].
Conversely, polysaccharide and nucleic acid fraction extracted from Mycobacterium bovis
bacillus Calmette–Guérin (BCG-PSN) could be used as a novel adjuvant of DNA vaccine to elicit
potent cellular and humoral immune responses against the HIV-1 Env antigen in BALB/c
mouse model. In this experiment, the BCG-PSN was mixed with 10 μg or 100 μg of DNA
vaccine and injected intramuscularly two or three times. BCG-PSN co-immunization with 10
μg DNA vaccine could elicit cellular and humoral immune responses which were comparable
to that induced by 100 μg DNA vaccine alone. Moreover, BCG-PSN could activate TLR
signaling pathways and induce Th1-type cytokine secretion. These findings suggested that
BCG-PSN can be applied as a new and effective adjuvant for DNA vaccination [73].
Chemokines are largely bioactive inflammatory molecules which play a major role in a variety
of immune and inflammatory responses, acting primarily as chemoattractants and activators
of various leukocytes. In addition, some chemokines play a critical role in the transmission
and progression of HIV-1 and HIV-2 viruses responsible for AIDS. Recent studies have
indicated that chemokines and their receptors may play an important role in the differentiation
and expansion of T cells in response to immune activation. These regulatory properties of
chemokines make them suitable as molecular adjuvants [84]. For example, the modulation and
regulation of immune responses were evaluated from the co-delivery of two β-chemokines as
gene expression cassettes, MIP-1α or RANTES, along with HIV-1 DNA immunogen constructs.
The data showed that MIP-1α had the greatest effect on antibody responses. In addition, co-
expression of MIP-1α also modulated the shift of immune responses to Th2-type (i.e., the
increase of IgG1/IgG2a ratio). RANTES co-immunization also enhanced the levels of antigen-
specific Th1 and CTL responses. The use of chemokine adjuvanted vaccines as HIV vaccine
modulators may be important due to the interesting relationship between HIV cell entry and
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the receptors for β-chemokines. Indeed, β-chemokines as vaccine adjuvants increased β-
chemokine production in an antigen-specific manner [84].
7. Heterologous prime-boost strategies
Most of the current DNA vaccines utilize CMV, β-actin, or muscle-specific desmin promoters
to potentiate expression of one or two fused genes of HIV-1 including the Env, Gag, Pol, and
Tat. DNA vaccines comprising multiple plasmids encoding different HIV-1 proteins have been
used to obtain a broader spectrum of immunity than individual plasmids expressing single
proteins. The use of these plasmid DNA vaccines proved to be safe and immunogenic in
macaques; however, these constructs needed to be boosted with viral proteins expressed by
various vector systems including recombinant pox virus, modified vaccinia virus Ankara, and
adenovirus for enhancing their efficiency in preventing AIDS [85].
The heterologous prime-boost regimen uses the ability of the immune system to generate large
numbers of secondary antigen-specific T cells following an initial priming step. The same
antigen is delivered subsequently using different vectors. Following a priming immunization,
the antigen-specific T-cell populations develop to modest levels and then reduce. Indeed, a
percentage of these cells transform into antigen-specific memory T cells. In a heterologous
boost, because the priming and boosting vectors are different, T cells that specifically target
the viral vector are not boosted and do not activate cell number control mechanisms, therefore
allowing for greater development of the disease antigen-specific T-cell populations [82].
Several groups have now established that heterologous prime-boost regimens are the most
potent strategies to induce cellular immune responses [86, 87]. In a plasmid DNA vaccine
priming and viral vector-boosting regimen, the order of DNA followed by recombinant virus
is important, as the reverse order did not induce higher levels of antigen-specific CD8+ T cells.
It seems that the cytokine microenvironment created by a local virus infection during boosting
is responsible for the efficient expansion of effector T cells [86]. In 2004, a consecutive immu‐
nization strategy involving priming with DNA and boosting with recombinant fowlpoxvirus
(rFPV) vaccines encoding multiple common HIV-1 antigens was evaluated in 30 macaques.
The vaccines were well tolerated, and a significant enhancement of DNA-vaccine primed
HIV-1-specific T-lymphocyte responses was observed following rFPV boosting. Co-expression
of IFNγ or IL-12 by the rFPV vaccines did not further enhance immune responses [88]. In
addition, a subtype A or B HIV gp160 plasmid DNA and Env gp140 trimeric glycoprotein co-
immunization was superior to immunization with glycoprotein alone by enhancing neutral‐
izing antibodies. These data showed that co-delivering DNA and protein can increase antibody
responses to Env. Hence, this approach has the potential to simplify vaccine regimens by
inducing higher antibody responses using fewer vaccinations, an advantage for a successful
HIV vaccine design [89].
The reports showed that co-immunization of a DNA vaccine encoding HIV-1P24-Nef with
GM-CSF in DNA priming and peptide boost strategy increases the immunogenicity of the
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candidate vaccine. Cytokine profile studies showed that both IL-4 and IFN-γ levels were
increased. Also, co-immunization with GM-CSF resulted in a higher level of total IgG,
comprising approximately equal levels of both specific IgG1 and IgG2a subtypes. Taken
together, the results suggested that GM-CSF is able to induce long-term memory for the HIV-1
P24-Nef vaccine candidate [90]. Recent studies have used DNA/protein or DNA/adeno-vector
regimens for HIV immunization. The essential mechanisms of heterogeneous prime/boost
regimens are not well understood, but DNA priming results in much lower antigen expression
compared to protein vaccines, and this may prime T-helper cell responses with the humoral
response subsequently being boosted by the high-dose protein or viral vector (e.g., RV 144
tested in clinical trials) [87].
8. Clinical trials
Several vaccine candidates were used in different phases of clinical trials. DNA prime-viral
vector boost regimens have become the primary choice for stimulation of T-cell immune
responses. For example, Poxvirus vector-based vaccines including the Modified Vaccinia
Ankara and the genetically modified NYVAC-based vaccines appeared to be efficient in
inducing the immune responses and could be evaluated in combination with DNA priming
in clinical trials [91]. In addition, the safety and immunogenicity of several Canarypox-based
vaccines with multiple HIV-1 gene inserts have been studied in humans. A phase III trial,
RV144, using Canarypox (vCP1521) prime and AIDSVAX B/E boost has demonstrated modest
protective efficacy in Thailand. The protection in RV144 trial was short-time and needed to
use the additional boosters in participants for improving recall responses and continuing
protection among them. AIDSVAX was also a component of the prime-boost (ALVAC/
AIDSVAX) RV 144 vaccine in Thailand that showed successful results. In both cases, the
vaccines targeted gp120 and were specific for the geographical regions. Among the adenoviral
vector vaccine candidates, replication-defective Ad5 candidate indicated high immunogenic‐
ity in phase I clinical trials and reduced viral load in the SHIV/NHP model. However, this
strategy failed to prevent new infections as well as reduce post-infection viral RNA levels in
the vaccinated individuals in phase IIb. Furthermore, participants with preexisting antibodies
against Ad5 vector showed increased HIV infection rates [91]. The heterologous prime-boost
strategy using DNA prime and Ad5 boost was considered to avoid the problem of preexisting
immunity. It has been shown that the preexisting Ad5-neutralizing antibodies did not affect
the levels of cell-mediated responses in the DNA/rAd5 prime-boost recipients, as compared
to participants who received rAd5 alone. However, in spite of robust immune responses
induced by DNA/Ad5 strategy in phase I and phase II trials, the strategy failed to show
protection from new infections in phase IIb [91]. Generally, prime-boost vaccination is an
efficient approach compared to other strategies, but it still needs to develop against HIV
infections in future.
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9. Challenges for HIV vaccines
There are some major challenges against HIV vaccine design as described below. Figure 1
shows these challenges briefly.
Figure 1. Challenges for HIV-preventive vaccines
9.1. Designing trimeric HIV-1 envelopes
The challenge remains to develop HIV-1 immunogens that will elicit protective immunity [13].
The challenge is to design, engineer, and produce a pure stable envelope immunogen that
mimics the antigenic profile of the functional envelope spike. The engineered trimeric envelope
was unable to induce bNAb in animals. Modification of the trimers, including removal of
individual glycans proximal to CD4-binding region, elimination of the glycosylation site near
the gp41 loop, linker-stabilized gp140 trimeric envelopes, have resulted in improved immu‐
nogenicity but have not yielded the desired bNAb. A combination of mosaic envelopes
increased the magnitude of NAbs but not the breadth of the response in macaques. Therefore,
no trimeric envelope induces bNAb in humans [1]. Some studies showed that HIV-1 bNAbs
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identifies four conserved Env targets for HIV neutralization. To date, more than 30 bNAbs
specific for conserved neutralizing Env epitopes have been characterized [17].
9.2. Why does vaccination with HIV envelope not induce bNAbs?
Whether bNAb will effectively confer protection against HIV infection in humans remains
unknown. An alternative to inducing bNAb by vaccination with immunogens is to deliver
these bnMAbs with viral vectors (e.g., adeno-associated virus (AAV) gene transfer vector
expressing antibodies or antibody-like immunoadhesins). This approach generated a long-
lasting neutralizing activity in serum of macaques conferring complete protection against
intravenous challenge with virulent SIVmac316. Similarly, full protection against intravenous
HIV-1 challenge was observed in humanized mice receiving AAV carrying b12, while those
receiving AAV carrying 2G12, 4E10, and 2F5 were partially protected [1]. A recent study has
demonstrated that up to 50% of HIV-infected individuals will make cross-reactive antibodies
that neutralize 50% of HIV primary strains. However, when bNAbs develop in HIV infection,
they only occur after 2–4 years of infection. In contrast, no vaccine immunizations to date have
induced high levels of bNAbs. The bNAbs are targeted to one of five conserved sites on the
HIV Env trimer: the CD4 binding site, the membrane proximal gp41 region, the V3-glycan site,
the V1V2-glycan site, and gp41-gp120 bridging regions [51]. Each of these sites is protected by
surrounding glycans, and each one of these sites is restricted in access, such that relatively few
antibody variable heavy (VHDJH) and variable light (VL) combinations may be used to bind
these Env sites. Example of restricted VHDJH/VL usage is the use of VH1-2 paired with a 5 aa
VL complementarity-determining region 3 (LCDR3) for the VRC01 type of CD4 binding site
bNAb, and the use of VH1-69, Vk3-20 for 4E10-like gp41 bNAbs. Moreover, all bNAbs have
one or more unusual features, including high levels of somatic mutations, and poly- or
autoreactivity that can result in immune tolerance control for bNAbs. However, in the simian-
human immunodeficiency virus rhesus macaque challenge model, passive infusion of the new
bNAbs could potently protect against SHIV challenge [51].
9.3. Effective adjuvants
Adjuvants are important for the use of recombinant envelope immunogens, since these
proteins by themselves generate only weak immune responses. For potent vaccine formula‐
tions delivered by mucosal routes, incorporation of adjuvants that controls the potential of
innate immune modulators is important for overcoming immune tolerance and enhancing the
immunogenicity of co-administered antigens [25]. The RV144 trial used alum as an adjuvant,
which was then the only licensed vaccine adjuvant. However, alum is not believed to support
robust cellular immune responses. Also, bacterial toxins are the most potent mucosal adjuvant
candidates but concerns remain regarding their safety even when mutated to reduce toxicity.
In contrast, ligands for TLRs 7/8 and 9 serve as potent adjuvants for parenteral and mucosal
vaccines based on plasmid DNA, viral vectors, and recombinant proteins [25]. In particular,
CpG-containing synthetic oligodeoxynucleotides (CpG-ODN) that activate TLR9 on dendritic
cells appear potent in stimulating antigen presentation and induction of antigen-specific
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immune responses. The synthetic glycolipid α-galactosylceramide has been tested primarily
in cancer immunotherapy studies because of its capacity to serve as a ligand and potent
activator of invariant natural killer T cells. In addition, the repeated mucosal delivery of α-
GalCer adjuvant was done in primary and booster immunizations that resulted in repeated
activation of NKT cells and DC to progressively increase adaptive immune responses [25]. The
parallel development of adjuvants along with better HIV-1 immunogens will be needed for a
successful AIDS vaccine. Additional comparative testing will be required to determine the
optimal adjuvant and immunogen regimen that can elicit antibody responses capable of
blocking HIV-1 transmission [92].
Both flagellin (fliC) and IL-18 (interferon-γ-inducing factor) have been developed as adjuvants
to improve immunogenicity in DNA-vaccinated hosts. An HIV-1 Gag plasmid encodes a
protein harboring broad epitopes for CTLs [93]. The immunogenicity of BALB/c mice immu‐
nized with an HIV-1 Gag plasmid (pVAX/Gag), combined with a chimeric plasmid encoding
IL-18 fused to flagellin (pcDNA3/IL-18_fliC) or a single plasmid encoding IL-18 (pcDNA3/
IL-18) and/or flagellin (pcDNA3/fliC), was studied. The IL-18 and flagellin fusion protein
effectively induced IFN-γ by lymphocytes. During a 12-week immunization, both Gag-specific
IgG in sera and spleen cell proliferation were elevated in all murine groups. However, the
IgG2a/IgG1 ratio, Th1 cytokine (IL-2 and IFN-γ) production, and the proportion of Gag-
specific CD3+ CD8+ IFN-γ-secreting cells were significantly increased in the murine group co-
immunized with the pVAX/Gag plasmid and pcDNA3/IL-18_fliC compared with the mice
immunized with the pVAX/Gag plasmid combined with either the pcDNA3/fliC or pcDNA3/
IL-18 plasmid or both of them. The data suggested that the chimeric plasmid encoding IL-18
fused to flagellin can be used as an adjuvant-like plasmid to improve the Th1 immune
response, particularly for the induction of CD3+ CD8+ IFN-γ-secreting cells in Gag plasmid-
vaccinated mice [93].
9.4. High mutation rate of HIV-1
The high mutation rate of HIV-1 and tolerance for genetic diversity represented central
challenges for vaccine design. Because the immune response is itself adaptive, the optimal
HIV-1 sequence within an individual also differs over time. HIV-1 develops specific mutations
within its genome that allow it to escape detection by human leukocyte antigen (HLA) class
I-restricted immune responses, notably those of CD8+ CTLs. HLA thus represents a major force
driving the evolution and diversity of HIV-1 within individuals [94].
9.5. Escaped variants
A major challenge is how to induce effective immune responses against escaped variants. It is
important that a CTL-based vaccine stimulate effective cellular responses across the range of
HLA class I alleles expressed in a host population. These observations have led to the idea that
immune-mediated control of HIV-1 replication to levels that slow disease progression might
be feasible through the design of vaccines that focus CTL responses against viral regions where
escape cannot occur [94]. To date, adenovirus vector prime and pox vector boost vaccines have
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been one among the most immunogenic vaccines for inducing HIV CD8 T-cell responses in
humans. Efforts continue to overcome HIV diversity for T-cell epitope recognition by the in
silico design of centralized consensus or mosaic HIV gene inserts based on optimizing the
coverage of T-cell epitopes in HIV strains in the Los Alamos HIV Sequence Database, or based
on conserved epitopes in the vaccine [51].
9.6. Expression of the bNAbs is limited by host tolerance mechanisms
The studies showed that two human recombinant bNAbs, called 2F5 and 4E10, that bind near
the virion membrane to Env gp41 were reactive in human autoantibody assays. In a subsequent
study, 2F5 was shown to avidly bind the human protein kynureninase (KYNU), and 4E10 was
shown to react with the mammalian RNA splicing factor 3B3. The nominal gp41 epitope of the
2F5 bNAb is the linear peptide ELDKWAS and an identical 6-residue sequence is present in
KYNU (ELDKWA). This ELDKWA motif in KYNU is conserved in nearly all mammalian
species and absent in all proteins other than the HIV Env. Thus, the autoantigens for these two
bNAbs, 2F5 and 4E10, have been identified, suggesting that expression of these bNAbs is
limited by host tolerance mechanisms [17].
9.7. Challenges for developing vaccines targeting viral glycan epitopes
Generation of antibodies to glycans has several challenges: a) due to the inherent weakness of
carbohydrate–protein interactions, binding affinities must be enhanced through avidity
effects. For example, lectins are able to overcome this problem using interaction of multiple
carbohydrate binding domains with arrays of glycan ligands; b) glycoproteins usually always
exist as a number of different glycoforms where the same protein backbone is glycosylated
with different glycan structures. This microheterogeneity weakens the antigenic response to
the individual glycan structures. These multiple conformations may be presented to the
immune system further weakening the response; c) glycosylation is ubiquitous to all mam‐
malian cells, thus the host may display tolerance toward these sugars. Generally, these effects
result in glycans are poorly immunogenic. The major concern of generating antibodies against
self-glycan structures is their potential autoreactivity in vivo [95].
9.8. Animal model for preclinical studies
There are few nonhuman primate models of enhanced HIV susceptibility [96]. Animal model
research during the past years has focused on the development of models in order to explore
key questions about HIV entry, immune control, and persistence and also their use for testing
therapeutic vaccines [97].
9.9. Design of new envelope immunogens
A major challenge for HIV-1 B-cell vaccine development is the design of new envelope
immunogens that can trigger the selection and expansion of germline precursor and inter‐
mediate memory B cells associated with the maturation of a broadly neutralizing antibody
response. The identification of delivery systems, prime-boost strategies, and synergistic
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adjuvant combinations is important to induce the magnitude and quality of antigen-specific
T-follicular helper cell responses needed to induce somatic hypermutation (SHM) and B-cell
maturation against heterologous primary virus envelopes [98].
9.10. Safety of vaccines
Safety of vaccines is one of the most important subjects for the design of vaccines that should
be determined in clinical trials [99].
9.11. Accessibility of the glycoconjugate vaccines
Accessibility of these glycoconjugate vaccines in resource-poor regions which bear the highest
disease burden from these pathogens remains challenging largely due to high vaccine pricing
[100].
9.12. Induction of potent and broadly cross-reactive neutralizing antibody responses
Induction of potent and broadly cross-reactive neutralizing antibody responses remains a
major challenge for the development of HIV vaccines because of the high diversity of gp120.
The high glycosylation, large conformational changes, and steric restriction of the epitopes in
gp120 during receptor binding and membrane fusion processes prevent the access of antibod‐
ies to these sites [101].
9.13. Challenges associated with antigen immunogenicity
The failure to date of Env-based antigens to stimulate bNAb is likely to result from several
specific reasons that influence BCR recognition of unusual structural antigenic elements:
a. Incorrect presentation of the vaccine antigen: Immunization with linear peptides of
MPER failed to re-elicit neutralizing responses because the MPER peptide mimics adopted
an inappropriate conformation in solution and failed to present the correct surface for B-
cell recognition [5].
b. Cross-reactivity with self: The 4E10 mAb, and to a lesser extent the 2F5 mAb, binds lipid
as part of their epitope by using an array of hydrophobic residues. This binding appears
to make them autoreactive, resulting in B-cell tolerance mechanisms [5].
c. Epitopes with steric constraints for BCR recognition: The CD4bs is an apparent target
for eliciting NAbs as it requires conservation for function, and needs to be exposed for
CD4 binding. In contrast, most infected individuals do not make CD4bs-specific bNmAbs.
The main reason is the intrinsic immunorecessive nature of the conserved segments of
CD4bs [5].
d. Unique antigenic features for BCR recognition: The 2G12 bNmAb has an epitope
composed entirely of oligomannose groups. The PG and PGT series of bNmAbs have
complex glycan–peptide binding surfaces in which the glycans are heterogeneous.
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Preparation of such epitopes will require powerful synthetic chemistry related to scaf‐
folded peptide design. Both MPER bNmAbs 2F5 and 4E10 require a lipid component to
their epitopes and up to now this has not been incorporated into a successful immunogen
[5].
e. Germline BCR recognition and requirement for extensive antibody affinity matura‐
tion: There are two possible consequences of the steric constraints imposed on BCRs
during the recognition of structurally unusual antigens: a) the frequency of germline BCRs
available to recognize such complex antigens will be low, thus an extensive degree of
affinity maturation will be required to generate a high-affinity bNAbs recognizing
structurally “difficult” epitopes; b) the germline BCR affinity for a bNmAb epitope may
be undetectable. A feasible outcome of these constraints is that the host will require long-
term antigen exposure to select and clonally expand the rare B cells with appropriate BCRs
and to affinity mature them into bNAbs, because most bNmAbs arise in individuals after
chronic HIV-1 infection [5].
f. Conceptual concerns relating to epitope recognition by BCRs: There are concerns that
isolating an epitope from its antigenic context will not lead to re-elicitation of the same
type of antibody against the epitope, which is a reasonable concern. However, although
an epitope mimic may not re-stimulate an antibody identical to the template bNmAb, it
may be sufficiently balance between elicited Ab and epitope mimic to allow specific
binding to trimeric Env. If this is achieved, trimeric Env may be used to boost and affinity
mature those B cells reactive with the epitope mimetic [5].
g. Responders and non-responders: The finding that among large cohorts of HIV-1-infected
individuals only a minor percentage makes a bNmAb response suggests that this may
apply also to responses to vaccination [5].
Finally, the key difficulty in the development of an HIV vaccine is our ignorance of the immune
responses that control viral replication, how these responses can be elicited, and how they can
be monitored [2]. The question of whether to focus on induction of antibody or CTLs continues
to be discussed in the HIV-1 field. However, evidence from many other vaccine-preventable
infectious diseases indicates that antibody titers correlate with protection from infection, but
CTL-mediated immune responses are required for protection against disease. This suggests
that a dual approach is still necessary. Aspects of CTL vaccine technology such as replicating
or persistent vectors may need to express Env-based antigens to allow long-term antigenic
exposure for the induction of bNAb. In contrast, approaches to elicit bNmAbs may need to be
immunologically compatible with the generation of a parallel CTL response.
9.14. Conclusions
The development of a safe and effective vaccine for HIV is a major global priority. To date,
efforts to design an HIV vaccine have not been successful due to HIV diversity, HIV integration
into the host genome, and ability of HIV to consistently evade antiviral immune responses.
While the RV144 immunization strategy remains a priority for future efficacy trials, newer
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prime-boost mosaic and conserved sequence immunization strategies inducing efficient and
long-time immune responses as well as the development of immunogens inducing broadly
neutralizing antibodies should be followed and tested in humans. Recent success in isolation
of potent broadly neutralizing antibodies, in discovery of mechanisms of bNAb induction and
atypical mechanisms of CD8 T-cell killing of HIV infected cells, has opened new ways for HIV
vaccine design. Indeed, the most protective HIV vaccine will require the combination of T-cell-
inducing and antibody-inducing vaccine candidates with appropriate adjuvant formulations,
since the innate and adaptive arms of the immune system cooperate for virus neutralization
and pathogen-infected cell elimination. In general, acceleration of vaccine discovery depends
on basic research and new technologies. Novel strategies should be safe, but rapidly tested in
humans.
10. Key points
• Development of a safe and effective vaccine for HIV is a major global priority
• Efforts to design an efficient HIV vaccine have not succeeded due to HIV diversity, HIV
integration into the host genome, and ability of HIV to consistently evade antiviral immune
responses
• The cost-effective and different HIV-1 vaccine approaches have recently attracted a special
interest
• Both antibodies and cell-mediated immune responses are considered to be important to
prevent HIV-1 infection in the mucosal compartment
• Novel prime-boost mosaic and conserved sequence immunization strategies as well as the
development of immunogens inducing broadly neutralizing antibodies have attracted a
special interest
• Recent success in isolation of potent broadly neutralizing antibodies, in discovery of
mechanisms of bNAb induction and atypical mechanisms of CD8 T-cell killing of HIV
infected cells, has opened new ways for HIV vaccine design
• Several therapeutic vaccine strategies have already been used such as live-attenuated
microbes, viral vectors, and dendritic cell-based vaccines that led to suppress and/or clear
HIV infections
• Among different vaccines, improved DNA vaccines have emerged as a promising candidate
for the treatment of infectious diseases especially HIV infections
• Some strategies have been considered to improve immune responses stimulated by DNA
vaccines such as in vivo efficient DNA delivery systems, co-delivery with molecular
adjuvants as well as the development of potent heterologous prime-boost regimens
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